BriaCell Therapeutics 12/14/2023 Earnings Report

BriaCell Therapeutics EPS Results

• Actual EPS: -C$6.70
• Consensus EPS: -C$2.50
• Beat/Miss: Missed by -C$4.20
• One Year Ago EPS: N/A

BriaCell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BriaCell Therapeutics Announcement Details

• Date: 12/14/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

BriaCell Therapeutics (TSE:BCT) is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.